Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Publisher Correction: Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma.

Trucco LD, Mundra PA, Hogan K, Garcia-Martinez P, Viros A, Mandal AK, Macagno N, Gaudy-Marqueste C, Allan D, Baenke F, Cook M, McManus C, Sanchez-Laorden B, Dhomen N, Marais R.

Nat Med. 2019 Feb;25(2):350. doi: 10.1038/s41591-018-0325-y.

PMID:
30560902
2.

Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma.

Trucco LD, Mundra PA, Hogan K, Garcia-Martinez P, Viros A, Mandal AK, Macagno N, Gaudy-Marqueste C, Allan D, Baenke F, Cook M, McManus C, Sanchez-Laorden B, Dhomen N, Marais R.

Nat Med. 2019 Feb;25(2):221-224. doi: 10.1038/s41591-018-0265-6. Epub 2018 Dec 3. Erratum in: Nat Med. 2018 Dec 18;:.

PMID:
30510256
3.

Functional interplay between secreted ligands and receptors in melanoma.

Herraiz C, Jiménez-Cervantes C, Sánchez-Laorden B, García-Borrón JC.

Semin Cell Dev Biol. 2018 Jun;78:73-84. doi: 10.1016/j.semcdb.2017.06.021. Epub 2017 Jul 1. Review.

PMID:
28676423
4.

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma.

Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BMJM, Menard D, McLeary R, Johnson L, Fish L, Ejiama S, Sanchez-Laorden B, Hohloch J, Carragher N, Macleod K, Ashton G, Marusiak AA, Fusi A, Brognard J, Frame M, Lorigan P, Marais R, Springer C.

Cancer Cell. 2017 Mar 13;31(3):466. doi: 10.1016/j.ccell.2017.02.007. No abstract available.

5.

Erratum: Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease.

Grande MT, Sánchez-Laorden B, López-Blau C, De Frutos CA, Boutet A, Arévalo M, Rowe RG, Weiss SJ, López-Novoa JM, Nieto MA.

Nat Med. 2016 Feb;22(2):217. doi: 10.1038/nm0216-217d. No abstract available.

PMID:
26845406
6.

Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease.

Grande MT, Sánchez-Laorden B, López-Blau C, De Frutos CA, Boutet A, Arévalo M, Rowe RG, Weiss SJ, López-Novoa JM, Nieto MA.

Nat Med. 2015 Sep;21(9):989-97. doi: 10.1038/nm.3901. Epub 2015 Aug 3. Erratum in: Nat Med. 2016 Feb;22(2):217.

PMID:
26236989
7.

Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.

Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BM, Menard D, McLeary R, Johnson L, Fish L, Ejiama S, Sanchez-Laorden B, Hohloch J, Carragher N, Macleod K, Ashton G, Marusiak AA, Fusi A, Brognard J, Frame M, Lorigan P, Marais R, Springer C.

Cancer Cell. 2015 Jan 12;27(1):85-96. doi: 10.1016/j.ccell.2014.11.006. Epub 2014 Dec 11. Erratum in: Cancer Cell. 2017 Mar 13;31(3):466.

8.

The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα.

Smith MP, Sanchez-Laorden B, O'Brien K, Brunton H, Ferguson J, Young H, Dhomen N, Flaherty KT, Frederick DT, Cooper ZA, Wargo JA, Marais R, Wellbrock C.

Cancer Discov. 2014 Oct;4(10):1214-1229. doi: 10.1158/2159-8290.CD-13-1007.

9.

Diverse matrix metalloproteinase functions regulate cancer amoeboid migration.

Orgaz JL, Pandya P, Dalmeida R, Karagiannis P, Sanchez-Laorden B, Viros A, Albrengues J, Nestle FO, Ridley AJ, Gaggioli C, Marais R, Karagiannis SN, Sanz-Moreno V.

Nat Commun. 2014 Jun 25;5:4255. doi: 10.1038/ncomms5255.

10.

Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53.

Viros A, Sanchez-Laorden B, Pedersen M, Furney SJ, Rae J, Hogan K, Ejiama S, Girotti MR, Cook M, Dhomen N, Marais R.

Nature. 2014 Jul 24;511(7510):478-482. doi: 10.1038/nature13298. Epub 2014 Jun 11.

11.

BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling.

Sanchez-Laorden B, Viros A, Girotti MR, Pedersen M, Saturno G, Zambon A, Niculescu-Duvaz D, Turajlic S, Hayes A, Gore M, Larkin J, Lorigan P, Cook M, Springer C, Marais R.

Sci Signal. 2014 Mar 25;7(318):ra30. doi: 10.1126/scisignal.2004815.

PMID:
24667377
12.

Mind the IQGAP.

Sanchez-Laorden B, Viros A, Marais R.

Cancer Cell. 2013 Jun 10;23(6):715-7. doi: 10.1016/j.ccr.2013.05.017.

13.

Differential and competitive regulation of human melanocortin 1 receptor signaling by β-arrestin isoforms.

Abrisqueta M, Herraiz C, Pérez Oliva AB, Sanchez-Laorden BL, Olivares C, Jiménez-Cervantes C, García-Borrón JC.

J Cell Sci. 2013 Aug 15;126(Pt 16):3724-37. doi: 10.1242/jcs.128322. Epub 2013 Jun 7.

14.

Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes.

Pedersen M, Küsters-Vandevelde HVN, Viros A, Groenen PJTA, Sanchez-Laorden B, Gilhuis JH, van Engen-van Grunsven IA, Renier W, Schieving J, Niculescu-Duvaz I, Springer CJ, Küsters B, Wesseling P, Blokx WAM, Marais R.

Cancer Discov. 2013 Apr;3(4):458-469. doi: 10.1158/2159-8290.CD-12-0464. Epub 2013 Jan 9.

15.

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer C, Larkin J, Jorgensen C, Marais R.

Cancer Discov. 2013 Feb;3(2):158-67. doi: 10.1158/2159-8290.CD-12-0386. Epub 2012 Dec 14.

16.

Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma.

Viros A, Hayward R, Martin M, Yashar S, Yu CC, Sanchez-Laorden B, Zambon A, Niculescu-Duvaz D, Springer C, Lo RS, Marais R.

J Invest Dermatol. 2013 Jan;133(1):274-6. doi: 10.1038/jid.2012.268. Epub 2012 Aug 16. No abstract available. Erratum in: J Invest Dermatol. 2013 Jun;133(6):1691.

17.

N-glycosylation of the human melanocortin 1 receptor: occupancy of glycosylation sequons and functional role.

Herraiz C, Sánchez-Laorden BL, Jiménez-Cervantes C, García-Borrón JC.

Pigment Cell Melanoma Res. 2011 Jun;24(3):479-89. doi: 10.1111/j.1755-148X.2011.00848.x. Epub 2011 Apr 5.

PMID:
21410905
18.

Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.

Arozarena I, Sanchez-Laorden B, Packer L, Hidalgo-Carcedo C, Hayward R, Viros A, Sahai E, Marais R.

Cancer Cell. 2011 Jan 18;19(1):45-57. doi: 10.1016/j.ccr.2010.10.029. Epub 2011 Jan 6.

19.

Aberrant trafficking of human melanocortin 1 receptor variants associated with red hair and skin cancer: Steady-state retention of mutant forms in the proximal golgi.

Sánchez-Laorden BL, Herraiz C, Valencia JC, Hearing VJ, Jiménez-Cervantes C, García-Borrón JC.

J Cell Physiol. 2009 Sep;220(3):640-54. doi: 10.1002/jcp.21804.

20.

Subcellular localization of antizyme inhibitor 2 in mammalian cells: Influence of intrinsic sequences and interaction with antizymes.

López-Contreras AJ, Sánchez-Laorden BL, Ramos-Molina B, de la Morena ME, Cremades A, Peñafiel R.

J Cell Biochem. 2009 Jul 1;107(4):732-40. doi: 10.1002/jcb.22168.

PMID:
19449338
21.

Mechanism of dimerization of the human melanocortin 1 receptor.

Zanna PT, Sánchez-Laorden BL, Pérez-Oliva AB, Turpín MC, Herraiz C, Jiménez-Cervantes C, García-Borrón JC.

Biochem Biophys Res Commun. 2008 Apr 4;368(2):211-6. doi: 10.1016/j.bbrc.2008.01.060. Epub 2008 Jan 24.

PMID:
18222116
22.

Regulation of human melanocortin 1 receptor signaling and trafficking by Thr-308 and Ser-316 and its alteration in variant alleles associated with red hair and skin cancer.

Sánchez-Laorden BL, Jiménez-Cervantes C, García-Borrón JC.

J Biol Chem. 2007 Feb 2;282(5):3241-51. Epub 2006 Nov 27.

23.

Variant amino acids in different domains of the human melanocortin 1 receptor impair cell surface expression.

Sánchez-Laorden BL, Sánchez-Más J, Turpín MC, García-Borrón JC, Jiménez-Cervantes C.

Cell Mol Biol (Noisy-le-grand). 2006 May 30;52(2):39-46.

PMID:
16914085
24.

Dimerization of the human melanocortin 1 receptor: functional consequences and dominant-negative effects.

Sánchez-Laorden BL, Sánchez-Más J, Martínez-Alonso E, Martínez-Menárguez JA, García-Borrón JC, Jiménez-Cervantes C.

J Invest Dermatol. 2006 Jan;126(1):172-81.

25.

Melanocortin-1 receptor structure and functional regulation.

García-Borrón JC, Sánchez-Laorden BL, Jiménez-Cervantes C.

Pigment Cell Res. 2005 Dec;18(6):393-410. Review.

PMID:
16280005
26.

The melanocortin-1 receptor carboxyl terminal pentapeptide is essential for MC1R function and expression on the cell surface.

Sánchez-Más J, Sánchez-Laorden BL, Guillo LA, Jiménez-Cervantes C, García-Borrón JC.

Peptides. 2005 Oct;26(10):1848-57.

PMID:
15993512

Supplemental Content

Loading ...
Support Center